Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry K Keefer

Showing results (21-30 of 117) with videos related to

Pageof 12
Sort By:
Organic Letters|October 9, 2007
Nitric oxide prodrugs: diazeniumdiolate anions of hindered secondary aminesHarinath Chakrapani, Brett M Showalter, Michael L Citro, et al.
Organic Letters|October 30, 2008
Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugsHarinath Chakrapani, Anna E Maciag, Michael L Citro, et al.
Bioorganic & Medicinal Chemistry|February 24, 2012
Diazeniumdiolated carbamates: a novel class of nitric oxide donorsRahul S Nandurdikar, Anna E Maciag, Zhao Cao, et al.
The Journal of Organic Chemistry|July 9, 2021
Piperazine as a Linker for Incorporating the Nitric Oxide-Releasing Diazeniumdiolate Group into Other Biomedically Relevant Functional MoleculesJoseph E Saavedra, Melissa N Booth, Joseph A Hrabie, et al.
Cancer Letters|July 31, 2007
The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosisWei Qu, Jie Liu, Richard Fuquay, et al.
Journal of Medicinal Chemistry|March 5, 2008
Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studiesCarlos A Velázquez, Qiao-Hong Chen, Michael L Citro, et al.
Nitric Oxide : Biology and Chemistry|October 16, 2013
Enzymatic generation of the NO/HNO-releasing IPA/NO anion at controlled rates in physiological media using β-galactosidaseRyan J Holland, Rika Paulisch, Zhao Cao, et al.
Cancer Science|January 22, 2009
V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicityWei Qu, Jie Liu, Anna L Dill, et al.
Journal of Medicinal Chemistry|December 5, 2008
Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activitiesDaniela Andrei, Anna E Maciag, Harinath Chakrapani, et al.
Molecular Cancer Therapeutics|January 7, 2004
Nitric oxide does not mediate but inhibits transformation and tumor phenotypeArindam Dhar, June M Brindley, Cristi Stark, et al.
Pageof 12

Showing results (21-30 of 117) with videos related to

Sort By:
Pageof 12
Organic Letters|October 9, 2007
Nitric oxide prodrugs: diazeniumdiolate anions of hindered secondary aminesHarinath Chakrapani, Brett M Showalter, Michael L Citro, et al.
Organic Letters|October 30, 2008
Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugsHarinath Chakrapani, Anna E Maciag, Michael L Citro, et al.
Bioorganic & Medicinal Chemistry|February 24, 2012
Diazeniumdiolated carbamates: a novel class of nitric oxide donorsRahul S Nandurdikar, Anna E Maciag, Zhao Cao, et al.
The Journal of Organic Chemistry|July 9, 2021
Piperazine as a Linker for Incorporating the Nitric Oxide-Releasing Diazeniumdiolate Group into Other Biomedically Relevant Functional MoleculesJoseph E Saavedra, Melissa N Booth, Joseph A Hrabie, et al.
Cancer Letters|July 31, 2007
The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosisWei Qu, Jie Liu, Richard Fuquay, et al.
Journal of Medicinal Chemistry|March 5, 2008
Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studiesCarlos A Velázquez, Qiao-Hong Chen, Michael L Citro, et al.
Nitric Oxide : Biology and Chemistry|October 16, 2013
Enzymatic generation of the NO/HNO-releasing IPA/NO anion at controlled rates in physiological media using β-galactosidaseRyan J Holland, Rika Paulisch, Zhao Cao, et al.
Cancer Science|January 22, 2009
V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicityWei Qu, Jie Liu, Anna L Dill, et al.
Journal of Medicinal Chemistry|December 5, 2008
Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activitiesDaniela Andrei, Anna E Maciag, Harinath Chakrapani, et al.
Molecular Cancer Therapeutics|January 7, 2004
Nitric oxide does not mediate but inhibits transformation and tumor phenotypeArindam Dhar, June M Brindley, Cristi Stark, et al.
Pageof 12